Hippo pathway and breast cancer stem cells

Marcello Maugeri-Saccà, Ruggero De Maria

Research output: Contribution to journalArticle

Abstract

Tumors contain a specialized subset of cells with unique properties, such as self-renewal and tumorigenic potential. These cancer stem-like cells (CSCs) are supposed to be responsible for therapeutic resistance and metastatic spread. Functional characterization of breast CSCs (BCSCs) is beginning to shed light on molecular networks which are specifically activated in this cellular compartment, and that account for the retention/acquisition of stem-like features. The Hippo tumor suppressor pathway has increasingly been tied to breast cancer. Altered Hippo activity, or Hippo-independent mechanisms, mediate the activation of the Hippo transducers TAZ and YAP. When this occurs, cancer cells acquire more aggressive traits. In the realm of BCSCs, improper TAZ/YAP activity sustains self-renewal, resistance to conventional anticancer agents, and metastatic dissemination. In this review, we highlight the involvement of TAZ and YAP in mammary gland development and in BCSCs. We also discuss potential strategies for transferring this information into the clinical setting.

Original languageEnglish
Pages (from-to)115-122
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume99
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Neoplastic Stem Cells
Breast Neoplasms
Breast
Neoplasms
Human Mammary Glands
Transducers
Antineoplastic Agents
Therapeutics

Keywords

  • Breast cancer
  • Cancer stem Cells
  • Hippo pathway

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Hippo pathway and breast cancer stem cells. / Maugeri-Saccà, Marcello; De Maria, Ruggero.

In: Critical Reviews in Oncology/Hematology, Vol. 99, 01.03.2016, p. 115-122.

Research output: Contribution to journalArticle

@article{dabb1de05df24343a6f1fb7ad9309bc5,
title = "Hippo pathway and breast cancer stem cells",
abstract = "Tumors contain a specialized subset of cells with unique properties, such as self-renewal and tumorigenic potential. These cancer stem-like cells (CSCs) are supposed to be responsible for therapeutic resistance and metastatic spread. Functional characterization of breast CSCs (BCSCs) is beginning to shed light on molecular networks which are specifically activated in this cellular compartment, and that account for the retention/acquisition of stem-like features. The Hippo tumor suppressor pathway has increasingly been tied to breast cancer. Altered Hippo activity, or Hippo-independent mechanisms, mediate the activation of the Hippo transducers TAZ and YAP. When this occurs, cancer cells acquire more aggressive traits. In the realm of BCSCs, improper TAZ/YAP activity sustains self-renewal, resistance to conventional anticancer agents, and metastatic dissemination. In this review, we highlight the involvement of TAZ and YAP in mammary gland development and in BCSCs. We also discuss potential strategies for transferring this information into the clinical setting.",
keywords = "Breast cancer, Cancer stem Cells, Hippo pathway",
author = "Marcello Maugeri-Sacc{\`a} and {De Maria}, Ruggero",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.critrevonc.2015.12.004",
language = "English",
volume = "99",
pages = "115--122",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Hippo pathway and breast cancer stem cells

AU - Maugeri-Saccà, Marcello

AU - De Maria, Ruggero

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Tumors contain a specialized subset of cells with unique properties, such as self-renewal and tumorigenic potential. These cancer stem-like cells (CSCs) are supposed to be responsible for therapeutic resistance and metastatic spread. Functional characterization of breast CSCs (BCSCs) is beginning to shed light on molecular networks which are specifically activated in this cellular compartment, and that account for the retention/acquisition of stem-like features. The Hippo tumor suppressor pathway has increasingly been tied to breast cancer. Altered Hippo activity, or Hippo-independent mechanisms, mediate the activation of the Hippo transducers TAZ and YAP. When this occurs, cancer cells acquire more aggressive traits. In the realm of BCSCs, improper TAZ/YAP activity sustains self-renewal, resistance to conventional anticancer agents, and metastatic dissemination. In this review, we highlight the involvement of TAZ and YAP in mammary gland development and in BCSCs. We also discuss potential strategies for transferring this information into the clinical setting.

AB - Tumors contain a specialized subset of cells with unique properties, such as self-renewal and tumorigenic potential. These cancer stem-like cells (CSCs) are supposed to be responsible for therapeutic resistance and metastatic spread. Functional characterization of breast CSCs (BCSCs) is beginning to shed light on molecular networks which are specifically activated in this cellular compartment, and that account for the retention/acquisition of stem-like features. The Hippo tumor suppressor pathway has increasingly been tied to breast cancer. Altered Hippo activity, or Hippo-independent mechanisms, mediate the activation of the Hippo transducers TAZ and YAP. When this occurs, cancer cells acquire more aggressive traits. In the realm of BCSCs, improper TAZ/YAP activity sustains self-renewal, resistance to conventional anticancer agents, and metastatic dissemination. In this review, we highlight the involvement of TAZ and YAP in mammary gland development and in BCSCs. We also discuss potential strategies for transferring this information into the clinical setting.

KW - Breast cancer

KW - Cancer stem Cells

KW - Hippo pathway

UR - http://www.scopus.com/inward/record.url?scp=84959490225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959490225&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.12.004

DO - 10.1016/j.critrevonc.2015.12.004

M3 - Article

AN - SCOPUS:84959490225

VL - 99

SP - 115

EP - 122

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -